RegentAtlantic Capital’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.31M | Sell |
4,905
-198
| -4% | -$42.1K | 0.04% | 263 |
|
|
2022
Q2 | $1.04M | Buy |
5,103
+1,391
| +37% | +$284K | 0.03% | 308 |
|
|
2022
Q1 | $782K | Sell |
3,712
-1,857
| -33% | -$404K | 0.02% | 367 |
|
|
2021
Q4 | $1.34M | Sell |
5,569
-1,229
| -18% | -$316K | 0.04% | 270 |
|
|
2021
Q3 | $1.92M | Buy |
6,798
+121
| +2% | +$39.7K | 0.06% | 213 |
|
|
2021
Q2 | $2.31M | Sell |
6,677
-300
| -4% | -$90.9K | 0.07% | 189 |
|
|
2021
Q1 | $1.95M | Sell |
6,977
-1,077
| -13% | -$290K | 0.07% | 192 |
|
|
2020
Q4 | $1.97M | Sell |
8,054
-586
| -7% | -$151K | 0.08% | 172 |
|
|
2020
Q3 | $2.45M | Sell |
8,640
-367
| -4% | -$102K | 0.11% | 133 |
|
|
2020
Q2 | $2.41M | Buy |
9,007
+337
| +4% | +$101K | 0.13% | 132 |
|
|
2020
Q1 | $2.74M | Sell |
8,670
-113
| -1% | -$34.3K | 0.21% | 110 |
|
|
2019
Q4 | $2.61M | Sell |
8,783
-224
| -2% | -$62.2K | 0.16% | 143 |
|
|
2019
Q3 | $2.1M | Buy |
9,007
+608
| +7% | +$142K | 0.14% | 155 |
|
|
2019
Q2 | $1.96M | Buy |
8,399
+2,935
| +54% | +$678K | 0.13% | 162 |
|
|
2019
Q1 | $1.29M | Buy |
5,464
+976
| +22% | +$307K | 0.09% | 200 |
|
|
2018
Q4 | $1.35M | Sell |
4,488
-575
| -11% | -$184K | 0.11% | 187 |
|
|
2018
Q3 | $1.79M | Sell |
5,063
-62
| -1% | -$21.3K | 0.14% | 170 |
|
|
2018
Q2 | $1.49M | Buy |
5,125
+447
| +10% | +$126K | 0.13% | 174 |
|
|
2018
Q1 | $1.28M | Sell |
4,678
-105
| -2% | -$32.6K | 0.11% | 195 |
|
|
2017
Q4 | $1.52M | Sell |
4,783
-300
| -6% | -$96.2K | 0.12% | 174 |
|
|
2017
Q3 | $1.59M | Buy |
5,083
+5
| +0.1% | +$1.48K | 0.14% | 163 |
|
|
2017
Q2 | $1.38M | Sell |
5,078
-90
| -2% | -$23.8K | 0.13% | 175 |
|
|
2017
Q1 | $1.41M | Buy |
5,168
+132
| +3% | +$37.3K | 0.13% | 165 |
|
|
2016
Q4 | $1.43M | Sell |
5,036
-257
| -5% | -$76.2K | 0.14% | 157 |
|
|
2016
Q3 | $1.66M | Buy |
5,293
+364
| +7% | +$108K | 0.17% | 139 |
|
|
2016
Q2 | $1.19M | Buy |
4,929
+110
| +2% | +$29K | 0.12% | 167 |
|
|
2016
Q1 | $1.25M | Buy |
4,819
+95
| +2% | +$25.1K | 0.14% | 149 |
|
|
2015
Q4 | $1.45M | Buy |
4,724
+1,059
| +29% | +$304K | 0.15% | 151 |
|
|
2015
Q3 | $1.07M | Sell |
3,665
-70
| -2% | -$23.1K | 0.1% | 179 |
|
|
2015
Q2 | $1.51M | Sell |
3,735
-75
| -2% | -$30.1K | 0.13% | 154 |
|
|
2015
Q1 | $1.61M | Sell |
3,810
-570
| -13% | -$225K | 0.14% | 147 |
|
|
2014
Q4 | $1.49M | Sell |
4,380
-609
| -12% | -$197K | 0.13% | 153 |
|
|
2014
Q3 | $1.65M | Sell |
4,989
-37
| -0.7% | -$12.2K | 0.15% | 137 |
|
|
2014
Q2 | $1.58M | Sell |
5,026
-201
| -4% | -$60.5K | 0.15% | 138 |
|
|
2014
Q1 | $1.6M | Sell |
5,227
-337
| -6% | -$107K | 0.16% | 134 |
|
|
2013
Q4 | $1.56M | Sell |
5,564
-341
| -6% | -$88.2K | 0.15% | 138 |
|
|
2013
Q3 | $1.42M | Sell |
5,905
-211
| -3% | -$47.2K | 0.16% | 135 |
|
|
2013
Q2 | $1.32M | Buy |
+6,116
| New | +$1.31M | 0.16% | 133 |
|
Other funds holding BIIB
RegentAtlantic Capital's BIIB Position: Q3 2022 in Review
RegentAtlantic Capital reduced its Biogen (BIIB) stake by 3.9% in Q3 2022, selling an estimated $42.1K and leaving 4,905 shares worth $1.31M. The position accounts for 0.04% of the portfolio, ranked #263.
RegentAtlantic Capital first reported a position in BIIB in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.74M in Q1 2020. 986 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- RegentAtlantic Capital held 4,905 shares of Biogen worth $1.31M as of Q3 2022.
- RegentAtlantic Capital sold 198 Biogen shares in Q3 2022, an estimated $42.1K.
- Biogen made up 0.04% of RegentAtlantic Capital's portfolio in Q3 2022, its #263 holding.
- RegentAtlantic Capital first reported a position in Biogen in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's Biogen position peaked at $2.74M in Q1 2020.
- 986 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.